Patent extension requests
Executive Summary
FDA review periods for three drugs determined. Merck's Prinivil (lisinopril) had a review period of 2,373 days (1,751 during IND and 622 during NDA); Merck is seeking 676 days of patent extension. Sterling's Corotrope (milrinone lactate) review period was 2,205 days (1,287 during IND and 918 during NDA); the company is seeking 730 days of patent extension. Kendall McGaw's Ucephan (sodium benzoate) had a 2,871 day review (2,058 IND; 813 NDA). Kendall is also seeking 730 days of patent extension. The Patent Office makes the final determination of the length of extension.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.